 Rintatolimod was tested in clinical trials in the United States beginning in 1988, after DuPont invested $30 million in Hemispherx.Initial success in a small trial for AIDS treatment was followed by difficulties in persuading the FDA to permit large scale trials.By 1991, it was thought that the chance of approval for a large trial being conducted in the USA had gone.